-
Product Insights
NewLikelihood of Approval Analysis for Secondary Progressive Multiple Sclerosis (SPMS)
Overview How likely is it that the drugs in Secondary Progressive Multiple Sclerosis (SPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secondary Progressive Multiple Sclerosis (SPMS) Overview Secondary progressive multiple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Foralumab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMS-001 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMS-001 in Secondary Progressive Multiple Sclerosis (SPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-97540 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-97540 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-97540 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Drugs In Development, 2023’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ofatumumab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ofatumumab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ofatumumab in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...